University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Arie Perry, MD

Arie Perry, MD

Professor of Pathology and Neurological Surgery; Director of Neuropathology; Director of Neuropathology Fellowship Training Program; Vice Chair of Pathology

Cancer Center Program Memberships

Neurologic Oncology

Research Summary

My clinical interests focus most heavily on surgical neuropathology, especially in terms of its application towards neuro-oncology. As a diagnostic neuropathologist with a focus on CNS tumors, I am primarily involved in translational research with the primary goal of developing new diagnostic and prognostic markers, which can be utilized in the clinical management of brain tumor patients. In order to achieve this goal, my lab has applied immunohistochemical, molecular cytogenetic, and genomic screening techniques primarily towards the study of gliomas, meningiomas, and primitive pediatric malignancies. I have been particularly interested in improved classification and grading schemes as well as the identification of molecular genetic markers associated with tumorigenesis, malignant progression, and/or biologic behavior. I collaborate with a number of clinical and scientific researchers both within and outside UCSF and it is our hope that the markers we identify will improve patient management and lead to the development of novel therapeutic approaches. I also maintain a private consultation service for difficult surgical neuropathology cases obtained from the U.S. and abroad, particularly brain tumors.

Education

The University of Texas at Austin, TX, B.S., 1986, Zoology
UT Southwestern Medical Center, Dallas, TX, M.D., 1990, M.D.
UT Southwestern Medical Center, Dallas, TX, Postdoctoral, 1994, Anatomic and Clinical Pathology Residency
Mayo Clinic, Rochester, MN, Postdoctoral, 1998, Surgical Pathology, Neuropathology, and Research Fellowships


Professional Experience

  • 1997-1998
    Mayo Clinic School of Medicine Instructor Pathology
  • 1998-2003
    Washington U. School of Medicine Assistant Professor Pathology
  • 2003-2008
    Washington U. School of Medicine Associate Professor Pathology
  • 2008-2010
    Washington U. School of Medicine Professor Pathology
  • 2009-2010
    Washington U. School of Medicine Professor Neurosurgery
  • 2010-present
    University of California, San Francisco Professor Pathology
  • 2010-present
    University of California, San Francisco Professor Neurosurgery

Honors & Awards

  • 1993
    First Place Resident Award (poster): Texas Society of Pathologists meeting
  • 1994
    First Place Resident Award (podium): Texas Society of Pathologists meeting
  • 1994
    Matthew T. Moore Award, International Congress of Neuropathology meeting
  • 1995
    Mary Tom Award, Canadian Association of Neuropathologists meeting
  • 1995-1997
    Fellowship Research Award, American Brain Tumor Association
  • 1999
    Distinguished Service Teaching Award, WUSM (Medical School Class of 2001)
  • 2002
    Lucien J. Rubenstein Award, American Association of Neuropathologists meeting
  • 2002
    Distinguished Service Teaching Award, WUSM (Medical School Class of 2004)
  • 2004
    Distinguished Service Teaching Award, WUSM (Medical School Class of 2006)
  • 2005
    Professor of the Year Award, WUSM (Medical School Class of 2007)
  • 2006-now
    America’s Top Doctors and America's Top Doctors for Cancer (Castle Connolly)
  • 2007
    Distinguished Service Teaching Award, WUSM (Medical School Class of 2009)
  • 2008
    Professor of the Year Award, WUSM (Medical School Class of 2010)
  • 2009-now
    Best Doctors in America, U.S. News and World Reports
  • 2009
    Distinguished Service Teaching Award, WUSM (Medical School Class of 2011)
  • 2013
    Nominated for MS1 Essential Core Teaching Award, UCSF (MS Class of 2016)

Selected Publications

  1. Johann PD, Bens S, Oyen F, Wagener R, Giannini C, Perry A, Raisanen JM, Reis GF, Nobusawa S, Arita K, Felsberg J, Reifenberger G, Agaimy A, Buslei R, Capper D, Pfister SM, Schneppenheim R, Siebert R, Frühwald MC, Paulus W, Kool M, Hasselblatt M. Sellar Region Atypical Teratoid/Rhabdoid Tumors (ATRT) in Adults Display DNA Methylation Profiles of the ATRT-MYC Subgroup. Am J Surg Pathol. 2018 Apr; 42(4):506-511.
    View on PubMed
  2. Vasudevan HN, Braunstein SE, Phillips JJ, Pekmezci M, Tomlin BA, Wu A, Reis GF, Magill ST, Zhang J, Feng FY, Nicholaides T, Chang SM, Sneed PK, McDermott MW, Berger MS, Perry A, Raleigh DR. Comprehensive Molecular Profiling Identifies FOXM1 as a Key Transcription Factor for Meningioma Proliferation. Cell Rep. 2018 Mar 27; 22(13):3672-3683.
    View on PubMed
  3. Chen WC, Hara J, Magill ST, Wu A, Aghi MK, Theodosopoulos PV, Perry A, McDermott MW, Sneed PK, Raleigh DR, Braunstein SE. Salvage therapy outcomes for atypical meningioma. J Neurooncol. 2018 Feb 26.
    View on PubMed
  4. Goode B, Mondal G, Hyun M, Ruiz DG, Lin YH, Van Ziffle J, Joseph NM, Onodera C, Talevich E, Grenert JP, Hewedi IH, Snuderl M, Brat DJ, Kleinschmidt-DeMasters BK, Rodriguez FJ, Louis DN, Yong WH, Lopes MB, Rosenblum MK, Butowski N, Tihan T, Bollen AW, Phillips JJ, Wiita AP, Yeh I, Jacobson MP, Bastian BC, Perry A, Solomon DA. A recurrent kinase domain mutation in PRKCA defines chordoid glioma of the third ventricle. Nat Commun. 2018 02 23; 9(1):810.
    View on PubMed
  5. Iorgulescu JB, Van Ziffle J, Stevers M, Grenert JP, Bastian BC, Chavez L, Stichel D, Buchhalter I, Samuel D, Nicolaides T, Banerjee A, Mueller S, Gupta N, Tihan T, Bollen AW, Northcott PA, Kool M, Pfister S, Korshunov A, Perry A, Solomon DA. Deep sequencing of WNT-activated medulloblastomas reveals secondary SHH pathway activation. Acta Neuropathol. 2018 Apr; 135(4):635-638.
    View on PubMed
  6. Pekmezci M, Stevers M, Phillips JJ, Van Ziffle J, Bastian BC, Tsankova NM, Kleinschmidt-DeMasters BK, Rosenblum MK, Tihan T, Perry A, Solomon DA. Multinodular and vacuolating neuronal tumor of the cerebrum is a clonal neoplasm defined by genetic alterations that activate the MAP kinase signaling pathway. Acta Neuropathol. 2018 Mar; 135(3):485-488.
    View on PubMed
  7. Wu A, Garcia MA, Magill ST, Chen W, Vasudevan HN, Perry A, Theodosopoulos PV, McDermott MW, Braunstein SE, Raleigh DR. Presenting Symptoms and Prognostic Factors for Symptomatic Outcomes Following Resection of Meningioma. World Neurosurg. 2018 Mar; 111:e149-e159.
    View on PubMed
  8. Lee JC, Pekmezci M, Lavezo JL, Vogel H, Katznelson L, Fraenkel M, Harsh G, Dulai M, Perry A, Tihan T. Utility of Pit-1 Immunostaining in Distinguishing Pituitary Adenomas of Primitive Differentiation from Null Cell Adenomas. Endocr Pathol. 2017 Dec; 28(4):287-292.
    View on PubMed
  9. Wood MD, Tihan T, Perry A, Chacko G, Turner C, Pu C, Payne C, Yu A, Bannykh SI, Solomon DA. Multimodal molecular analysis of astroblastoma enables reclassification of most cases into more specific molecular entities. Brain Pathol. 2018 03; 28(2):192-202.
    View on PubMed
  10. Lopez GY, Oberheim Bush NA, Phillips JJ, Bouffard JP, Moshel YA, Jaeckle K, Kleinschmidt-DeMasters BK, Rosenblum MK, Perry A, Solomon DA. Diffuse midline gliomas with subclonal H3F3A K27M mutation and mosaic H3.3 K27M mutant protein expression. Acta Neuropathol. 2017 Dec; 134(6):961-963.
    View on PubMed
  11. Korshunov A, Chavez L, Sharma T, Ryzhova M, Schrimpf D, Stichel D, Capper D, Sturm D, Kool M, Habel A, Kleinschmidt-DeMasters BK, Rosenblum M, Absalyamova O, Golanov A, Lichter P, Pfister SM, Jones DTW, Perry A, von Deimling A. Epithelioid glioblastomas stratify into established diagnostic subsets upon integrated molecular analysis. Brain Pathol. 2017 Oct 09.
    View on PubMed
  12. Rogers L, Zhang P, Vogelbaum MA, Perry A, Ashby LS, Modi JM, Alleman AM, Galvin J, Brachman D, Jenrette JM, De Groot J, Bovi JA, Werner-Wasik M, Knisely JPS, Mehta MP. Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539. J Neurosurg. 2017 Oct 06; 1-13.
    View on PubMed
  13. Mazor T, Chesnelong C, Pankov A, Jalbert LE, Hong C, Hayes J, Smirnov IV, Marshall R, Souza CF, Shen Y, Viswanath P, Noushmehr H, Ronen SM, Jones SJM, Marra MA, Cairncross JG, Perry A, Nelson SJ, Chang SM, Bollen AW, Molinaro AM, Bengtsson H, Olshen AB, Weiss S, Phillips JJ, Luchman HA, Costello JF. Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant IDH1. Proc Natl Acad Sci U S A. 2017 Oct 03; 114(40):10743-10748.
    View on PubMed
  14. Higham CS, Steinberg SM, Dombi E, Perry A, Helman LJ, Schuetze SM, Ludwig JA, Staddon A, Milhem MM, Rushing D, Jones RL, Livingston M, Goldman S, Moertel C, Wagner L, Janhofer D, Annunziata CM, Reinke D, Long L, Viskochil D, Baker L, Widemann BC. SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors. Sarcoma. 2017; 2017:8685638.
    View on PubMed
  15. Chan AK, Han SJ, Choy W, Beleford D, Aghi MK, Berger MS, Shieh JT, Bollen AW, Perry A, Phillips JJ, Butowski N, Solomon DA. Familial melanoma-astrocytoma syndrome: synchronous diffuse astrocytoma and pleomorphic xanthoastrocytoma in a patient with germline CDKN2A/B deletion and a significant family history. Clin Neuropathol. 2017 Sep/Oct; 36(5):213-221.
    View on PubMed
  16. Barajas RF, Villanueva-Meyer J, Perry A, Berger M, Cha S. Biologically aggressive regions within glioblastoma identified by spin-lock contrast T1 relaxation in the rotating frame (T1?) MRI. Radiol Case Rep. 2017 Dec; 12(4):827-832.
    View on PubMed
  17. Pekmezci M, Cuevas-Ocampo AK, Perry A, Horvai AE. Significance of H3K27me3 loss in the diagnosis of malignant peripheral nerve sheath tumors. Mod Pathol. 2017 Dec; 30(12):1710-1719.
    View on PubMed
  18. Chan E, Bollen AW, Sirohi D, Van Ziffle J, Grenert JP, Kline CN, Tihan T, Perry A, Gupta N, Solomon DA. Angiocentric glioma with MYB-QKI fusion located in the brainstem, rather than cerebral cortex. Acta Neuropathol. 2017 Oct; 134(4):671-673.
    View on PubMed
  19. Banerjee A, Jakacki RI, Onar-Thomas A, Wu S, Nicolaides T, Young Poussaint T, Fangusaro J, Phillips J, Perry A, Turner D, Prados M, Packer RJ, Qaddoumi I, Gururangan S, Pollack IF, Goldman S, Doyle LA, Stewart CF, Boyett JM, Kun LE, Fouladi M. A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study. Neuro Oncol. 2017 Aug 01; 19(8):1135-1144.
    View on PubMed
  20. Sorge C, Li R, Singh S, Reddy AT, Solomon DA, Perry A, Friedman GK. Complete durable response of a pediatric anaplastic oligodendroglioma to temozolomide alone: Case report and review of literature. Pediatr Blood Cancer. 2017 Dec; 64(12).
    View on PubMed

Go to UCSF Profiles, powered by CTSI